Phospholipids and Lipid-Based Formulations in Oral Drug Delivery

被引:313
作者
Fricker, Gert [1 ,7 ]
Kromp, Torsten [6 ]
Wendel, Armin [6 ,7 ]
Blume, Alfred [5 ,7 ]
Zirkel, Juergen [4 ,7 ]
Rebmann, Herbert [4 ,7 ]
Setzer, Constanze [4 ,7 ]
Quinkert, Ralf-Olaf [4 ,7 ]
Martin, Frank [3 ,7 ]
Mueller-Goymann, Christel [2 ,7 ]
机构
[1] Heidelberg Univ, Inst Pharm & Mol Biotechnol, D-69120 Heidelberg, Germany
[2] Tech Univ, Inst Pharmaceut Technol, D-38106 Braunschweig, Germany
[3] iMEDD Inc, Columbus, OH USA
[4] Lipoid GmbH, D-67065 Ludwigshafen, Germany
[5] Martin Luther Univ Halle Wittenberg, Inst Chem, D-06120 Halle, Germany
[6] Phospholipid GmbH, D-50829 Cologne, Germany
[7] Phospholipid Res Ctr, D-69120 Heidelberg, Germany
关键词
emulsion; liposome; phospholipid; self-emulsifying drug delivery systems; solid lipid nanoparticles; INTESTINAL LYMPHATIC TRANSPORT; CYCLOSPORINE-A; IN-VIVO; PROLIPOSOMAL SYSTEMS; NANOPARTICLES SLN; BODY DISTRIBUTION; COATED LIPOSOMES; CARRIER SYSTEM; NEW-MODEL; ABSORPTION;
D O I
10.1007/s11095-010-0130-x
中图分类号
O6 [化学];
学科分类号
070301 [无机化学];
摘要
Phospholipids become increasingly important as formulation excipients and as active ingredients per se. The present article summarizes particular features of commonly used phospholipids and their application spectrum within oral drug formulation and elucidates current strategies to improve bioavailability and disposition of orally administered drugs. Advantages of phospholipids formulations not only comprise enhanced bioavailability of drugs with low aqueous solubility or low membrane penetration potential, but also improvement or alteration of uptake and release of drugs, protection of sensitive active agents from degradation in the gastrointestinal tract, reduction of gastrointestinal side effects of non-steroidal anti-inflammatory drugs and even masking of bitter taste of orally applied drugs. Technological strategies to achieve these effects are highly diverse and offer various possibilities of liquid, semi-liquid and solid lipid-based formulations for drug delivery optimization.
引用
收藏
页码:1469 / 1486
页数:18
相关论文
共 114 条
[1]
Anand BS, 1999, AM J GASTROENTEROL, V94, P1818
[2]
CALCITONIN-LOADED LIPOSOMES - STABILITY UNDER ACIDIC CONDITIONS AND BILE SALTS-INDUCED DISRUPTION RESULTING IN CALCITONIN-PHOSPHOLIPID COMPLEX-FORMATION [J].
ARIEN, A ;
HENRYTOULME, N ;
DUPUY, B .
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 1994, 1193 (01) :93-100
[3]
Cyclosporin nanoparticulate lipospheres for oral administration [J].
Bekerman, T ;
Golenser, J ;
Domb, A .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2004, 93 (05) :1264-1270
[4]
STUDIES OF INTESTINAL DIGESTION AND ABSORPTION IN THE HUMAN [J].
BORGSTROM, B ;
DAHLQVIST, A ;
LUNDH, G ;
SJOVALL, J .
JOURNAL OF CLINICAL INVESTIGATION, 1957, 36 (10) :1521-1536
[5]
Caliph SM, 2000, J PHARM SCI, V89, P1073, DOI 10.1002/1520-6017(200008)89:8<1073::AID-JPS12>3.0.CO
[6]
2-V
[7]
CAO J, 2009, DRUG DEV IND PHARM
[8]
Sirolimus (rapamycin, Rapamune®) and combination therapy with cyclosporin A in the rat developing adjuvant arthritis model:: Correlation with blood levels and the effects of different oral formulations [J].
Carlson, RP ;
Hartman, DA ;
Ochalski, SJ ;
Zimmerman, JL ;
Glaser, KB .
INFLAMMATION RESEARCH, 1998, 47 (08) :339-344
[9]
SECRETION AND CONTRIBUTION TO LIPOLYSIS OF GASTRIC AND PANCREATIC LIPASES DURING A TEST MEAL IN HUMANS [J].
CARRIERE, F ;
BARROWMAN, JA ;
VERGER, R ;
LAUGIER, R .
GASTROENTEROLOGY, 1993, 105 (03) :876-888
[10]
Lipid - An emerging platform for oral delivery of drugs with poor bioavailability [J].
Chakraborty, Subhashis ;
Shukla, Dali ;
Mishra, Brahmeshwar ;
Singh, Sanjay .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2009, 73 (01) :1-15